Statistics for Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial
Total visits
| views | |
|---|---|
| Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial | 11 |
Total visits per month
| views | |
|---|---|
| January 2024 | 10 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
File Visits
| views | |
|---|---|
| Journal.pdf | 6 |
Top country views
| views | |
|---|---|
| South Africa | 11 |
Top city views
| views | |
|---|---|
| Johannesburg | 11 |